Share this article
Share this article
MINNEAPOLIS, Feb. 11, 2021 /PRNewswire/ Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has recently published a paper entitled
Exosome-based Liquid Biopsies in Cancer: Opportunities and Challenges (Yu, W et al.), in the highly rated peer-reviewed journal,
Annals of Oncology (link). This review paper provides unique insight into liquid biopsies and the field of exosomes in the context of other liquid biopsies such as cfDNA and CTC analysis. The exosome field has gone through a rapid growth phase in parallel with the increasing attention over the potential of liquid biopsies. Despite recent progress of liquid biopsies for late-stage cancers, there remains a need to improve both the accuracy and utility of these tests, especially in earlier stage cancers. This will likely require a combination of approaches that exploit biomarkers released through different processes. Exosomes are released
BeMetals Reports Significant Copper and Silver Drill Intersections at Its High-Grade Polymetallic South Mountain Project
saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
MINNEAPOLIS, Feb. 3, 2021 /PRNewswire/ Bio-Techne Corporation (NASDAQ: TECH) today announced that ProteinSimple, a Bio-Techne brand, has expanded its Simple Plex
TM immunoassay cartridge portfolio to include nine new cartridge formats. These new cartridge offerings provide Simple Plex users with increased flexibility in the number of samples and biomarker assays run on each cartridge. Simple Plex assay cartridges, run on the Ella
TM platform, utilizing state-of-the-art microfluidics to deliver a fully automated immunoassay solution. Researchers can customize cartridge lots from a menu of over 200 validated assays. Until now, Simple Plex assay cartridges were only available in formats delivering one, four, or eight assays run simultaneously. The expanded portfolio of cartridge offerings provides users new options to better align their assay panels with the throughput requirements of their studies.
Share this article
Share this article
MINNEAPOLIS, Feb. 2, 2021 /PRNewswire/ Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended December 31, 2020. The quarterly dividend will be payable February 26, 2021 to all common shareholders of record on February 12, 2021. Future cash dividends will be considered by the Board of Directors on a quarterly basis.
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $739 million in net sales in fiscal 2020 and has over 2,30
Share this article
Share this article
MINNEAPOLIS, Feb. 2, 2021 /PRNewswire/ Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ended December 31, 2020.
Second Quarter FY2021 Snapshot
Second quarter organic revenue increased by 19% (21% reported) to $224.3 million and 15% (16% reported) in the first half of fiscal 2021 to $428.5 million.
GAAP EPS was $1.15 versus $3.02 one year ago primarily relating to a non-recurring gain of approximately $121 million in our ChemoCentryx investment in the second quarter of fiscal 2020. Delivered record adjusted earnings per share (EPS) of $1.62 versus $1.08 one year ago.
Adjusted Operating Margin increased to 38.7% in the second quarter of fiscal 2021 compared to 33.4% in the second quarter of fiscal 2020.
vimarsana © 2020. All Rights Reserved.